PH26548A - Compositions with enhanced penetration - Google Patents

Compositions with enhanced penetration Download PDF

Info

Publication number
PH26548A
PH26548A PH38267A PH38267A PH26548A PH 26548 A PH26548 A PH 26548A PH 38267 A PH38267 A PH 38267A PH 38267 A PH38267 A PH 38267A PH 26548 A PH26548 A PH 26548A
Authority
PH
Philippines
Prior art keywords
composition
solvent
diphenhydramine
agent
drug
Prior art date
Application number
PH38267A
Other languages
English (en)
Inventor
Majid Mahjour
Bernadette Mauser
Zahra A Rashidbaigi
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32512850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH26548(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Priority claimed from ZA91624A external-priority patent/ZA91624B/xx
Publication of PH26548A publication Critical patent/PH26548A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Physical Water Treatments (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Laminated Bodies (AREA)
PH38267A 1988-03-08 1989-03-01 Compositions with enhanced penetration PH26548A (en)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US16532288A 1988-03-08 1988-03-08
ZA91624A ZA91624B (en) 1991-01-28 1991-01-28 Delivery device for compositions with enhanced penetration and process for preparing same
NZ236921A NZ236921A (en) 1988-03-08 1991-01-28 Laminate for transmembranal administration of a drug
AU70061/91A AU634015B2 (en) 1988-03-08 1991-01-29 Compositions with enhanced penetration
IE30591A IE64308B1 (en) 1988-03-08 1991-01-29 Compositions with enhanced penetration
CA002035143A CA2035143A1 (en) 1988-03-08 1991-01-29 Compositions with enhanced penetration
FI910455A FI910455A7 (fi) 1988-03-08 1991-01-30 Parannetun läpäisevyyden omaava koostumus
KR1019910001750A KR100191456B1 (ko) 1988-03-08 1991-02-01 침투력이 향상된 조성물
NO91910403A NO910403L (no) 1988-03-08 1991-02-01 Fremgangsmaate for fremstilling av farmasoeytisk preparat.
JP3038921A JPH04338325A (ja) 1988-03-08 1991-02-12 増強された浸透性を有する組成物
PT96779A PT96779B (pt) 1988-03-08 1991-02-15 Laminado composito de duas camadas
EP91102354A EP0499662B1 (de) 1988-03-08 1991-02-19 Mittel mit erhöhtem Penetrationsvermögen

Publications (1)

Publication Number Publication Date
PH26548A true PH26548A (en) 1992-08-19

Family

ID=32512850

Family Applications (1)

Application Number Title Priority Date Filing Date
PH38267A PH26548A (en) 1988-03-08 1989-03-01 Compositions with enhanced penetration

Country Status (16)

Country Link
EP (2) EP0332147B1 (de)
JP (2) JP2939264B2 (de)
KR (1) KR100191456B1 (de)
AT (2) ATE90571T1 (de)
AU (2) AU611771B2 (de)
CA (1) CA2035143A1 (de)
DE (2) DE68907081T2 (de)
DK (2) DK175621B1 (de)
ES (2) ES2056981T3 (de)
FI (1) FI910455A7 (de)
GR (1) GR3014988T3 (de)
IE (2) IE62871B1 (de)
NO (1) NO910403L (de)
NZ (2) NZ228094A (de)
PH (1) PH26548A (de)
PT (1) PT96779B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE62871B1 (en) * 1988-03-08 1995-03-08 Warner Lambert Co Compositions with enhanced penetration
WO1991015176A1 (en) * 1990-04-06 1991-10-17 Pharmetrix Corporation Device and method for enhanced administration of physostigmine
DE4334919A1 (de) * 1993-10-13 1995-04-20 Liedtke Pharmed Gmbh Grenzwertig wirksame Arzneiformen mit Betablockern
US5869088A (en) * 1994-10-24 1999-02-09 Nikken Chemicals Co., Ltd Transdermal administration preparation of a 9-aminocyclopenta (b) quinoline
DE19533089C1 (de) * 1995-09-07 1997-05-22 Hexal Ag Tacrin-Pflaster
DE19533772C1 (de) * 1995-09-12 1998-01-02 Hexal Ag Tacrin/Selegilin-Pflaster
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6998138B2 (en) 1996-02-19 2006-02-14 Acrux Dds Pty. Ltd. Topical delivery of anti-alopecia agents
US6923983B2 (en) 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
US6916487B2 (en) 1996-02-19 2005-07-12 Acrux Dds Pty Ltd Transdermal delivery of antiemetics
US6916486B2 (en) 1996-02-19 2005-07-12 Acrux Dds Pty Ltd Transdermal delivery of analgesics
US7094422B2 (en) 1996-02-19 2006-08-22 Acrux Dds Pty Ltd. Topical delivery of antifungal agents
US6646379B1 (en) 1998-12-25 2003-11-11 Matsushita Electric Industrial Co., Ltd. Metal vapor discharge lamp having cermet lead-in with improved luminous efficiency and flux rise time
AU770365B2 (en) * 1998-12-11 2004-02-19 Bakulesh Mafatlal Khamar The process for manufacturing formulation of topical beta blockers with improved efficacy
DE10004790B4 (de) * 2000-02-01 2004-09-09 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung von Zaleplon, Verfahren zu seiner Herstellung und seine Verwendung
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
FR2870125B1 (fr) * 2004-05-12 2010-03-26 Dermaconcept Jmc Formulation du type spot-on utile en cosmetologie et en dermatologie
SI1937276T1 (sl) 2005-10-12 2013-04-30 Unimed Pharmaceuticals, Llc C/O Abbott Laboratoires 100 Abbott Park Road Izboljšani testosteronski gel in postopek uporabe
JP5052558B2 (ja) * 2009-04-03 2012-10-17 ロート製薬株式会社 ゲル軟膏

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3239183A1 (de) * 1981-10-23 1983-05-05 L'Oreal, 75008 Paris Wasserfreies, oxydationsstabiles mittel zur behandlung der haut
DE3333639A1 (de) * 1983-09-17 1985-03-28 Dynamit Nobel Ag Zubereitung von nitroestern fuer die koronartherapie
US4649075A (en) * 1984-08-09 1987-03-10 Leonora Jost Transdermal and transmucosal vortexed foam devices and the method of making
DE3685895T2 (de) * 1985-02-25 1992-12-24 Univ Rutgers Dosierungssystem fuer transdermale absorption von arzneimittelwirkstoffen.
US4816456A (en) * 1986-10-01 1989-03-28 Summers William K Administration of monoamine acridines in cholinergic neuronal deficit states
AU607172B2 (en) * 1986-12-22 1991-02-28 Cygnus, Inc. Diffusion matrix for transdermal drug administration
US5023084A (en) * 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
IE62871B1 (en) * 1988-03-08 1995-03-08 Warner Lambert Co Compositions with enhanced penetration

Also Published As

Publication number Publication date
KR920016085A (ko) 1992-09-24
ATE114481T1 (de) 1994-12-15
JPH01272519A (ja) 1989-10-31
DE69105480T2 (de) 1995-04-06
NZ228094A (en) 1991-09-25
DE69105480D1 (de) 1995-01-12
AU3025889A (en) 1989-09-14
DK0499662T3 (da) 1995-05-15
PT96779B (pt) 1998-09-30
AU7006191A (en) 1992-08-20
ES2056981T3 (es) 1994-10-16
DK175621B1 (da) 2004-12-27
IE64308B1 (en) 1995-07-26
ATE90571T1 (de) 1993-07-15
FI910455A0 (fi) 1991-01-30
EP0499662A1 (de) 1992-08-26
NO910403D0 (no) 1991-02-01
DE68907081T2 (de) 1993-10-21
NZ236921A (en) 1993-08-26
EP0332147A3 (en) 1990-09-19
GR3014988T3 (en) 1995-05-31
DE68907081D1 (de) 1993-07-22
EP0332147B1 (de) 1993-06-16
JPH04338325A (ja) 1992-11-25
NO910403L (no) 1992-08-03
AU611771B2 (en) 1991-06-20
IE910305A1 (en) 1992-07-29
FI910455L (fi) 1992-07-31
KR100191456B1 (ko) 1999-06-15
DK109689D0 (da) 1989-03-07
EP0499662B1 (de) 1994-11-30
ES2064780T3 (es) 1995-02-01
PT96779A (pt) 1992-08-31
CA2035143A1 (en) 1992-07-30
IE62871B1 (en) 1995-03-08
IE890390L (en) 1989-09-08
DK109689A (da) 1989-09-09
JP2939264B2 (ja) 1999-08-25
AU634015B2 (en) 1993-02-11
FI910455A7 (fi) 1992-07-31
EP0332147A2 (de) 1989-09-13

Similar Documents

Publication Publication Date Title
US5019395A (en) Compositions with enhanced penetration
EP0332147B1 (de) Mittel mit erhöhtem Penetrationsvermögen
CN113811306A (zh) 用于治疗周围神经病变的局部制剂
KR20070008690A (ko) 항콜린제를 위한 침투 강화 조성물
CA2360300C (en) A transdermal composition of an antivomiting agent and a preparation containing the same
JP5738727B2 (ja) 爪用貼付剤
JP2555555B2 (ja) 抗真菌性外用製剤
KR20050062627A (ko) 펜타닐 경피 외용 접착제
KR100423666B1 (ko) 항진균 외용 제제
EP1522316A1 (de) Transdermales absorptionspräparat
US5932227A (en) Percutaneously administrable base composition and drug composition prepared therefrom
US20050181031A1 (en) Solifenacin transdermal preparation and method for enhancing transdermal permeation thereof
KR20140016276A (ko) 첩부제 및 첩부 제제
US20080188509A1 (en) Transdermal Preparations and Method for Relieving Side Effects in Pergolide Therapy
IE64061B1 (en) External preparation containing amusulosin
KR20140016277A (ko) 첩부제 및 첩부 제제
KR102090424B1 (ko) 기능이 개선된 플라스터제
JP2008169145A (ja) 経皮適用製剤
JP2006016382A (ja) 貼付剤
WO2017006974A1 (ja) 経皮吸収型貼付剤
EP4529924B1 (de) Transdermales therapeutisches system mit cytisin
JP4895458B2 (ja) 経皮吸収促進剤およびその使用
EA049900B1 (ru) Состав для местного применения для лечения периферических нейропатий
JPS61204117A (ja) 経皮吸収外用剤
JP2016216384A (ja) 経皮吸収型製剤